Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 2 (2005), Issue 10 (October)

1. Blood pharmacokinetics of various monoclonal antibodies labeled with a new trifunctional chelating reagent for simultaneous conjugation with 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid and biotin before radiolabeling.
   Clin Cancer Res, 11(19): 7171s-7177s. [Abstract] [Full-text]
2. Adjuvant therapy of breast cancer.
   Cancer Invest, 23(6): 548-60. [Abstract] [Full-text]
3. Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer.
   Oncogene, 24(44): 6657-66. [Abstract] [Full-text]
4. The future of fulvestrant ("Faslodex").
   Cancer Treat Rev, 31: S26-33. [Abstract] [Full-text]
5. Response of bilateral choroidal metastases of breast cancer to therapy with trastuzumab.
   Breast, 14(5): 380-3. [Abstract] [Full-text]
6. Trastuzumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: report on six patients.
   Eur Urol, 48(5): 771-5; discussion 775-8. [Abstract] [Full-text]
7. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
   N Engl J Med, 353(16): 1673-84. [Abstract] [Full-text]
8. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
   N Engl J Med, 353(16): 1659-72. [Abstract] [Full-text]
9. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.
   Ann Oncol, 16(11): 1772-7. [Abstract] [Full-text]
10. Biological properties of a human compact anti-ErbB2 antibody.
    Carcinogenesis, 26(11): 1890-5. [Abstract] [Full-text]
11. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance.
    Breast Cancer Res Treat, 93: 11-8. [Abstract] [Full-text]
12. Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer.
    Drug News Perspect, 18(6): 375-85. [Abstract] [Full-text]
13. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC).
    Onkologie, 28(11): 582-6. [Abstract] [Full-text]
14. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
    Onkologie, 28(11): 558-64. [Abstract] [Full-text]
15. alpha-Particle Radioimmunotherapy of Disseminated Peritoneal Disease Using a (212)Pb-Labeled Radioimmunoconjugate Targeting HER2.
    Cancer Biother Radiopharm, 20(5): 557-68. [Abstract] [Full-text]
16. Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer.
    Cancer Lett, 230(1): 33-46. [Abstract] [Full-text]
17. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
    J Clin Oncol, 23(31): 7820-6. [Abstract] [Full-text]
18. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
    J Clin Oncol, 23(31): 7811-9. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.